Critique of FDA’s latest SSRI Data Analysis
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
Two Press Briefings are planned to demonstrate the multiple flaws in FDA's methodology and to provide credible science-based information.
"the first-ever randomized, placebo-controlled trial for the alleviation of post-traumatic stress disorder (PTSD)" reports: "we found that it really offered patients no benefits of any symptoms." [1]
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
This is an addendum to yesterday's Infomail in which we disseminated disinformation issued by the U.S. Center for Disease Control (CDC). www.ahrp.org/cms/content/view/396/80
Steven Fiorello, former Chief Pharmacist for the State of Pennsylvania, was arraigned on on Tuesday, November 21, 2006, on Felony and Misdemeanor charges related to his accepting money from drug companies whose drugs he put on the state Formulary.
Today's news report circulated by the media about the negative findings of a much touted, but uncontrolled observational study of depression (STAR*D) promotes the business interests of SSRI antidepressant drug manufacturers.
"Some politicians, public health officials, mental health activists and pharmaceutical companies have worked to establish mental-health screening programs in schools and the community….Researchers and clinicians, meanwhile, say they are far from having developed accurate predictors of a child developing depression. The younger the child, the murkier the crystal ball."
Alliance for Human Research Protection in the Press Feb 17, 2005: FDA Critics Slam Plan for Safety Reform – Nature “This is smoke and mirrors and musical chairs,” says Vera Sharav, president of the New York-based Alliance for Human Research Protection. “They will be using the very same officials that…
Congressional Investigations Senate Finance Committee Investigates FDA Aug 4: Sen. Grassley letter (416 K pdf) to 8 drug companies requests list of all antidepressant tests on children (1/1/1990–7/23/2004) Aug 3: Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data Jul 15: Senate Letter to FDA re: disclosure of risks…
FDA Slaps Pfizer on Zoloft Ads After AHRP Files Complaint Sat, 07 May 2005 On November 4, 2004, AHRP filed a complaint with the FDA about a two page Pfizer advertisement for its SSRI antidepressant, Zoloft. The ad appeared in The New York Times Magazine in October 2004, but Pfizer…